EIGR Eiger BioPharmaceuticals, Inc.

7.65
0  -3%
Previous Close 7.85
Open 7.85
Price To book 1.61
Market Cap 63.96M
Shares 8,361,000
Volume 61,324
Short Ratio 5.82
Av. Daily Volume 32,508

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data presented December 9, 2016.
Subcutaneous exendin
Post-Bariatric Hypoglycemia (PBH)
Phase 2 dosing commenced October 2016.
Pegylated Interferon Lambda (LIMT HDV)
Hepatitis delta virus (HDV)
Phase 2 end of trial data due 2Q 2017. Meeting with FDA scheduled for 4Q 2017.
Lonafarnib - LOWR HDV
Chronic hepatitis delta virus (HDV)
Phase 2 presentation at AASLD November 14, 2016.
Lonafarnib - LOWR HDV – 4
Chronic hepatitis delta virus (HDV)
Phase 2 presentation at AASLD November 14, 2016.
Lonafarnib - LOWR HDV – 3
Chronic hepatitis delta virus (HDV)
Phase 2 initiated July 2016. Enrollment to be completed 2Q 2017 with data due 1Q 2018.
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2 dosing commenced July 2016. Enrollment to be completed 3Q 2017. Data due 2Q 2018.
Ubenimex - ULTRA
Secondary lymphedema
Phase 2b negative data released April 2015. Formerly CLDN pre-merger
MYDICAR - CUPID 2 Trial
Ischemic or dilated cardiomyopathy

Latest News

  1. Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago
  2. Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017
  3. Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia
  4. Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting
  5. Eiger BioPharma reports 4Q loss
  6. Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
  7. Eiger BioPharmaceuticals to Present at the ROTH and Oppenheimer Investor Conferences in March 2017
  8. Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
  9. Eiger Completes $25 Million Debt Financing with Oxford Finance
  10. Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)
  11. How Five Star Quality Care, Inc. (FVE) Stacks Up Against Its Peers
  12. Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)
  13. Eiger BioPharmaceuticals, Inc. :EIGR-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  14. Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH)
  15. Eiger BioPharmaceuticals to Participate in Two Investor Conferences in November 2016
  16. Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting
  17. Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program
  18. Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results
  19. Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection
  20. Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)